Navigation Links
Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod)

gen to prevent clot formation and reduces blood viscosity, which may lead to improved blood flow within the affected area. Ancrod also indirectly causes the clot to break up. In contrast, other approved drugs or drugs in clinical development for AIS do not directly target fibrinogen. Ancrod has multiple mechanisms of action to help rapidly achieve three biological effects: blood viscosity reduction, thrombus modification, and alteration of hemostasis. The three effects of ancrod provide a potent yet potentially safe means of limiting brain damage with stroke.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. (NTI) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. The Company is focused on therapies for neurological conditions that occur in connection with ischemic stroke, brain cancer, Alzheimer's disease and dementia. The Company's strategy is to in- license and develop later-stage drug candidates that target major medical needs and that can be rapidly commercialized. NTI's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. For further information, please visit NTI's website at http://www.ntii.com.

A full press kit is available at the NTI booth (#171) or by emailing: Kamala@corinthgroup.com

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our need for additional capital, risks related to clinical trials and the regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, the risks associated with the cost of clinical developme
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Inspire Announces Presentations at Two European Scientific Conferences
6. IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
7. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
8. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
9. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
10. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
11. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
Post Your Comments:
(Date:6/20/2013)... WESTMINSTER, Colo. , June 20, 2013 ... Surefire Medical today announced a sales and marketing partnership ... catheters for the interventional radiology and oncology markets. ... range of products in the company,s rapidly growing ... . Sirtex reported a 30 per cent growth ...
(Date:6/20/2013)... , June 20, 2013 Today ... mark the launch of a new programme to control the ... Jacobina in the State of Bahia. In previous ... is possible to rapidly reduce the number of dengue mosquitoes ... the level of these mosquitoes were reduced by 96% within ...
(Date:6/19/2013)... 2013 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... England Journal of Medicine ( NEJM ) published ... oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients ... suggested ibrutinib may be effective and generally well-tolerated in ... a separate study examining the safety and efficacy of ...
Breaking Medicine Technology:Sirtex To Distribute Surefire Medical's Innovative Infusion System in Australia and Asia Pacific Markets 2Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue 2Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6
... Emdeon Inc. (NYSE: EM ), a leading provider ... acquisition of Chapin Revenue Cycle Management, LLC ("Chapin"). Based in ... revenue cycle services including accounts receivable management, medical denials, appeals and ... , ...
... June 21 TMS Health, a leading Healthcare Communications Company ... PA. , , ... TMS Health has enjoyed strong growth as a specialized healthcare ... and marketing reach of its clients. The company provides solutions for ...
Cached Medicine Technology:Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 2Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 3Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 4TMS Health Announces New State-of-the Art Facility in Moosic, PA 2
(Date:6/20/2013)... The ISA (International Seabuckthorn Association) founded ... announced their 6th annual international conference to take place ... , Bruce McMullin , Founder and CEO of ... for introducing the benefits of sea buckthorn to the ... Sibu grows and harvests sea buckthorn berries in the ...
(Date:6/20/2013)... Indianapolis, IN (PRWEB) June 20, 2013 ... Many employers are concerned that this cost percentage will ... burden of caring for both aging parents and adult ... claims management can either provide workers a road block, ... , United Benefit Advisors (UBA), in ...
(Date:6/20/2013)... York, New York (PRWEB) June 20, 2013 ... protein folding and misfolding, Navneet Tyagi has ... Alzheimer’s disease. Throughout the myriad of scientific research that ... his commitment of identifying early onset of these severe ... through early diagnosis, more medical researchers will be able ...
(Date:6/20/2013)... Denton, TX (PRWEB) June 20, 2013 ... has maintained a wide range of outpatient and inpatient ... psychiatric issues, including those who are children. As a ... UBH explains that it is critical to diagnose mental ... action. However, according to a recent article ...
(Date:6/20/2013)... June 20, 2013 Rampant staph infections ... to fight this scourge is being successfully deployed by ... direct contact and by touching items that are contaminated ... As noted by the San Francisco Chronicle , ... become infected during hospital stays, and at least 90,000 ...
Breaking Medicine News(10 mins):Health News:Sibu, LLC CEO, Bruce McMullin to be Amongst Distinguished Attendees at ISA Conference 2Health News:United Benefit Advisors and Symetra Host Absence Management Webinar 2Health News:United Benefit Advisors and Symetra Host Absence Management Webinar 3Health News:Navneet Tyagi Supports Continued Efforts for Alzheimer Detection Procedures 2Health News:Navneet Tyagi Supports Continued Efforts for Alzheimer Detection Procedures 3Health News:New Statistics Indicate Increase in Mental Health Issues Among Children, UBH Denton Responds 2Health News:New Statistics Indicate Increase in Mental Health Issues Among Children, UBH Denton Responds 3Health News:Lab Testing Reveals EnviroTextile's Hemp Fabric Stops the Spread of Staph Bacteria 2Health News:Lab Testing Reveals EnviroTextile's Hemp Fabric Stops the Spread of Staph Bacteria 3
... gene respond well to targeted therapy , , SUNDAY, June ... the normal version of a particular gene are more ... adding the targeted therapy Erbitux to chemotherapy. , Some ... "wild-type" form of the gene, according to the new ...
... cells, hasten death, study says , , SUNDAY, June 1 ... in cancer patients may actually speed progression of the ... found a way to determine who those individuals are. ... whether a patient is susceptible to having their tumor ...
... study suggests , , SUNDAY, June 1 (HealthDay News) -- ... value in helping to prevent lung cancer. , Researchers ... on the U.S. market, may reduce levels of a ... presented its findings Sunday at the American Society of ...
... combination of two different biotherapies may be beneficial for ... Pittsburgh Cancer Institute (UPCI) study presented at the 44th ... (ASCO) in Chicago. , Researchers in the melanoma and ... treatments that stimulate the immune system to fight cancer ...
... common types, study says , , SUNDAY, June 1 (HealthDay News) ... or adolescents are much more likely than other people to ... disease (HD), a cancer of the lymph nodes, has a ... be at future risk of developing second cancers other than ...
... in determining how much fathers get involved in taking care ... of 97 couples found that fathers were more involved in ... encouragement from their wife or partner. , In fact, this ... mothers views about how involved dads should be, the overall ...
Cached Medicine News:Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 2Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 3Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 2Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 3Health News:Young Hodgkin Survivors Face Later Risk of Second Cancers 2Health News:Mom's behavior key to dad's involvement in child care 2Health News:Mom's behavior key to dad's involvement in child care 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: